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Abstract
Background: This study was undertaken to evaluate the feasibility, safety, and therapeutic effects of percutaneous
renal cryoablation under local anesthesia with conscious sedation for patients who have unresectable stage 1
(T1NoMo) renal cell carcinoma (RCC) in high surgical risk.
Methods: Eighteen patients who were not candidates for surgery underwent primary cryosurgery guided by
gray-scale ultrasound. Contrast-enhanced ultrasonography (CEUS) and contrast-enhanced computed tomography
(CT) were performed to evaluate treatment at completion.
Results: The mean follow-up period was 26.8 months (range, 12–56 months). All tumors were biopsied before
cryosurgery. Seventeen tumors remained free of enhancement during follow-up period. No major complications
associated with cryoablation procedures were found though two instances of subcapsular hematomas, one of
retroperitoneal errhysis and one of nausea, were seen after cryoablation. One patient had a local recurrence of
tumor and received additional cryoablation. Local tumor control rate was 100 % of T1NoMo tumors including the
recurrence case who underwent additional cryoablation.
Conclusions: Percutaneous cryoablation can be recommended as a feasible, safe, and promising therapy for the
treatment of renal tumor, especially those unresectable stage 1 RCC, with a low risk of complications.
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Background
By reason of the incidental detection of small and
asymptomatic masses with the widespread use of im-
aging techniques, the incidence of renal cell carcinoma
has increased by severalfold during the past two decades
[1, 2]. Despite that less invasive surgical procedures such
as laparoscopic partial nephrectomy [3] and laparoscopic
renal cryoablation [4] have been performed in select pa-
tients, the demand for further reductions in therapy and
general anesthesia related to morbidity is desirable.
However, particularly in high-risk patients, an even less
invasive treatment such as percutaneous renal cryoa-
blation would be feasible. For some high-surgical-risk
patients, we were able to perform percutaneous cryoa-
blation under local anesthesia with conscious sedation
for unresectable stage 1 (T1NoMo) renal cell carcin-
oma (RCC). In our study, we evaluated the feasibility,
safety, and therapeutic effects of percutaneous renal
cryoablation for patients with high surgical risk after a
2-year mean follow-up.
Methods
Patients and eligibility criteria
From April 2009 to July 2013, 18 selective patients with
T1NoMo RCC underwent percutaneous renal cryoabla-
tion. All patients gave their informed consent and Nanjing
Drum Tower Hospital's ethics committee approved the
study protocol. Twelve men and six women with mean
age of 62 years (range, 41–89 years) were included in
this study. A total of ten tumors were found in the right
kidney and eight in the left. The mean tumor size was
3.3 ± 1.2 cm (range, 1.4–4.6 cm). All tumors were exo-
phytic. All of 18 patients had T1NoMo tumors accord-
ing to the TNM staging system. All patients were not
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candidates for surgery due to the fact that they are re-
ceiving treatment for other cancers (n = 3), age >85 years
old and refusal of surgical treatment (n = 4), hemophilia
(n = 1), coronary heart disease (n = 6), end-stage renal
disease receiving hemodialysis (n = 2), dilated cardiomy-
opathy (DCM) with heart failure (n = 2). Patients’ char-
acteristics and eligibility criteria are summarized in
Table 1. The diagnosis of RCC was based on the results
of needle biopsy before cryosurgery.
Percutaneous renal cryoablation procedures
All cryoablation procedures were performed using the
Cryo-Hit System (Galil Medical Ltd, Israel) by a single
urologist. All patients were placed in a modified lateral
position after induction with local anesthesia. Under
ultrasound (US) guidance, 1.47 mm 17G IceSeed cryo-
needles were placed into the renal tumor. The number
of cryoneedles varied with the size of tumor. Freezing
with argon gas to < −40 °C was initiated and monitored
using the temperature-monitoring probes, and US
guidance, which revealed an acoustic shadow as the ice
ball formed. After maintaining −40 °C or the lowest
temperature below −25 °C for 10 to 15 min, a passive
thaw was initiated until the temperature reached a
plateau. At this point, active thawing with helium was
started. Two cycles of rapid freeze–thaw was carried
out, ensuring the temperature in the renal tumor and
just outside it was below a therapeutic value of −40 °C.
At the end of the procedure, the needles and probes
were removed and pressure applied to location for
10 min to reduce bruising.
Evaluation at follow-up
Therapeutic effects were evaluated by contrast-enhanced
ultrasonography (CEUS) and contrast-enhanced com-
puted tomography (CT) 1 month after percutaneous
renal cryoablation. Subsequent CEUS and contrast-
enhanced CT assessment were performed after cryoa-
blation for additional follow-up imaging at 3, 6, and
every 6 months thereafter. All lesions that showed the
non-enhancing ablation zone on CEUS and contrast-
enhanced CT was considered to be a successful cryoa-
blation. The second cryoablation treatment was per-
formed additionally when an enhancing area of cancer
tissue was still present. Renal function of each patient
was evaluated with serum creatinine and the glomerular fil-
tration rate (GFR = 175 × (serum creatinine) × 11.54(age) ×
0.203 × (0.742 if female) × (1.210 if black)) [5].
Results
Procedures and therapeutic effects
Cryoablation proved to be technically successful in all
patients under local anesthesia with conscious sedation,
and tumors were considered completely ablated after at
least two follow-up sessions. Patients could tolerate renal
cryoablation successfully with minimal requirements for
pain medication and without the need for blood
transfusions. The mean duration of cryosurgery was
59.7 ± 11.6 min. The mean length of stay in the hos-
pital for the patients after cryoablation was 3.2 ±
1.2 days. One patient had a recurrence of tumor
1 year later and accepted additional cryoablation. As
the image showed a sequential image at a 2-year
follow-up, it demonstrated the size reduction and
disappearance of tumor’s enhancement of the ablated le-
sion completely for the longest time after two cryoabla-
tions (Figs. 1 and 2). Figure 1a showed contrast-enhanced
CT obtained before cryosurgery showed enhancement of
the tumor. Figures 1b and 2a demonstrated absence of en-
hancement of the ablated tumor 1 month after stage 1
cryotherapy. Figures 1c and 2b showed an enhancing area
of cancer tissue was still present 12 months after stage 1
cryotherapy. The patient was then scheduled to have a
stage 2 cryotherapy. Figures 1d and 2c demonstrated no
enhancement of the ablated lesions 1 month after stage 2
Table 1 Characteristics of patients and tumors for percutaneous
cryoablation
Patient characteristics Result
Patients (n) 18
Mean age (range) 62 (41–89)
Sex (n male/female) 12/6
Body mass index (kg/m2) 22.2 ± 3.7
The combined surgical risk factors:
Receiving treatment for other cancers 3
Age >85 years old and refusal of surgery 4
Hemophilia 1
Coronary heart disease 6
End-stage renal disease receiving hemodialysis 2
Dilated cardiomyopathy with heart failure 2
Mean follow-up (range), months 26.8 (12–56)
Mean tumor size (range), cm 3.3 (1.4–4.6)
Tumor location (right/left) 10/8
Pathology:
Clear cell RCC 14
Papillary RCC 3
Chromophobe RCC 1
Operative time (min) 67 ± 18
Complication
Nausea 3
Pain 4
Subcapsular hemorrhage 1
Retroperitoneal errhysis 1
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cryotherapy. Figures 1e and 2d demonstrated no growth
or enhancement of those lesions 12 months after stage 2
cryotherapy.
Complications
No major complications were found during the proce-
dures though intraoperative complications such as nausea
and pain, but nausea and pain are within tolerable limits
in all patients. As postoperative complications, one patient
had subcapsular hemorrhage and another one had retro-
peritoneal errhysis. No patient required dialysis, either
temporary or permanent. The pre- and post-cryoablation
mean serum creatinine levels were 1.2 ± 0.7 mg/dL and
1.3 ± 0.6 mg/dL, respectively. Also, no significant differ-
ences were found in the pre- and post-cryoablation mean
glomerular filtration rate (49.7 ± 22.1 mL/min and 50.1 ±
21.7 mL/min, respectively).
Follow-up findings
Seventeen of eighteen tumors were confirmed com-
pletely ablated and had no growth or enhancement
during the mean follow-up period of 26.8 months. All
tumors had a significant reduction from 3.3 ± 1.2 cm to
2.7 ± 1.1 cm (P < 0.05) observed at the last follow-up
examination after cryoablation. Only one tumor measur-
ing 2.8 cm was confirmed incompletely ablated by
contrast-enhanced CT scan 12 months after the procedure
and underwent re-cryoablation. No metastases of any tu-
mors were found during the follow-up period. The recur-
rence rate of RCC after successful cryoablation was 5.5 %
(1/18). The local tumor control rate was 100 % including
the recurrence case that underwent re-cryoablation.
Discussion
The role of various forms of minimally invasive therapies
has been greatly expanded to the previous standard of
open radical nephrectomy. Although partial nephrec-
tomy remains the reference standard, ablative techniques
are increasingly applied in the management of small
renal tumors with the long-term results emerging [6].
Among ablative modalities, cryotherapy is the most
widely used and accepted, especially for older patients in
Fig. 1 Sequential contrast-enhanced CT images of the ablation area of renal cell carcinoma (RCC) measuring 2.8 cm observed for the longest
period with two cryoablations. a Contrast-enhanced CT before cryotherapy. b Contrast-enhanced CT 1 month after stage 1 cryotherapy. c
Contrast-enhanced CT 12 months after stage 1 cryotherapy. d Contrast-enhanced CT 1 month after stage 2 cryotherapy. e Contrast-enhanced
CT 12 months after stage 2 cryotherapy
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high risk [7], and has shown to correlate with minimal
complications and good intermediate-term oncologic
outcomes [8]. The application of cryoablation is to ablate
solid tumors found in the lung, liver, breast, kidney, and
prostate. Prostate and renal cryoablation are the most
common. Although sometimes cryoablation is applied
through laparoscopic or open surgical approaches, most
often cryoablation is performed percutaneously. The ad-
vantages of percutaneous renal cryoablation include a
less-invasive procedure, shorter hospitalization, excellent
ice ball monitoring with ultrasound, less requirement for
pain medication, and lower risk of metastatic progres-
sion [9–11]. Most of all, it can be performed repeatedly
[12]. Compared to other thermal ablation, cryoablation
offers real-time, visual feedback of the ice ball and it is
nearly painless during the procedure, eliminating the
need of general anesthesia or deep sedation. Percutan-
eous renal cryoablation can be performed by ultrasound,
CT, or MRI guidance. Ultrasound is convenient and suf-
ficient for precise needle placement, and what is more, it
allows real-time guidance. The selected patients in this
study are all not candidates for surgical procedure be-
cause they are not could not tolerate the postoperative
pain and complications which general anesthesia brings.
As a matter of fact, the most common sequelae are
self-limited pain and paresthesia at the sites of probe in-
sertion related to cryoablation. Other complications that
are rare include hemorrhage, infection, visceral injury,
pneumothorax, and delayed UPJ obstruction. Mild peri-
nephric hematoma, myoglobinaemia, and transfusion
have been reported [13–15], but in most cases, those
complications could be managed rightly without operative
Fig. 2 Sequential contrast-enhanced ultrasound images of the ablation area of renal cell carcinoma (RCC) observed for the period with two
cryoablations. a Contrast-enhanced ultrasound 1 month after stage 1 cryotherapy. b Contrast-enhanced ultrasound 12 months after stage 1
cryotherapy. c Contrast-enhanced ultrasound 1 month after stage 2 cryotherapy. d Contrast-enhanced ultrasound 12 months after stage
2 cryotherapy
Yan et al. World Journal of Surgical Oncology  (2015) 13:200 Page 4 of 5
procedure. By placing the cryoprobe perpendicularly into
the kidney, carefully maintaining its position throughout
the procedure, and deliberately removing the probe after
complete thawing of renal tissue surrounding the cryo-
probe, renal fracture and hemorrhage can be avoided [7].
Uzzo and Novick published a cumulative total of 155
(13.7 %) complications in 1129 procedures in a review of
nephron-sparing surgical procedures during the past dec-
ade [16]. These complications include 14 deaths, 78 urin-
ary fistulas, 3 splenic injuries, 19 infections or abscesses,
27 hemorrhages, and 18 patients had to receive postopera-
tive dialysis [16]. The results of cryoablation in our study
are superior to this standard, especially when one con-
siders that many high-risk patients would not be candi-
dates for surgical procedure. Atwell reported the
durability of this treatment method with a low incidence
of tumor recurrence beyond 3 months in a midterm
follow-up of 93 tumors of percutaneous renal cryoablation
[17]. Our recurrence rate of stage 1 RCC after successful
cryoablation during a 2-year follow-up was 5.5 % (1/18).
However, the repeated treatment was performed later
resulting in the elimination of tumor enhancement. Al-
though the local ablated tumor control was 100 % of pa-
tients including the recurrence case that received
additional cryoablation at 2-year follow-up, we still need
further investigation of the long-term safety and efficacy
in tumor control. Moreover, in order to strengthen the
treatment, cryoablation can be combined with preopera-
tive or postoperative radiation therapy and chemotherapy
treatment, which can be in our follow-up study.
Conclusions
In summary, the result of our study showed percutan-
eous renal cryoablation is recommended as a feasible,
safe, and treatment modality for select patients with
unresectable stage 1 RCC, especially those older ones
with high surgical risk. Long-term efficacy will be deter-
mined by continued maturation of data.
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